オプションチェーンは、PepGenの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、PepGenの市場センチメントを評価します。.

PepGen (NASDAQ:PEPG) 株価情報, オプションチェーン

PEPGEN INC

PepGen

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

PepGen Inc

TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading golf technology company, today announced that the Nasdaq Hearings Panel has granted the company an extension of time to comply with Nasdaq listing rules subject to panel conditions. The Company's listing will be transferred to the Capital Market, effective at the open of business on June 3, 2025.&nbsp;

News

TRUG

TruGolf Secures Nasdaq Compliance Extension, Subject To Panel Conditions

Galloway Capital Partners And Affiliate, Diveroli Investment Group, Announces 4.31% Stake in Babcock & Wilcox Enterprises

WIIM

KURA

Kura Oncology shares are trading higher after the company announced the  FDA has granted it acceptance and priority review for Ziftomenib.

Litchfield Hills analyst Theodore O'Neill initiates coverage on Inspira Technologies Oxy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) with a Buy rating and announces Price Target of $2.

Price Target

Initiation

Analyst Ratings

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Litchfield Hills Initiates Coverage On Inspira Technologies Oxy with Buy Rating, Announces Price Target of $2

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance
Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors.

ERAS

Erasca Secures FDA Clearance For First-In-Class Pan-KRAS Inhibitor ERAS-4001

LQDA

Liquidia shares are trading higher after the company announced it began shipping its newly FDA-approved Yutrepia. Additionally, Needham raised its price target on the stock from $25 to $32.

Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Chronic Rhinosinusitis (CRS)</a>.
The ENLIGHTEN 2 trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a composite of the three cardinal symptoms (3CS) of CRS (nasal obstruction, nasal discharge, facial pain/pressure) at week 24 (p=0.0078) in patients without nasal polyps.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44083934/amgen-astrazeneca-partnered-asthma-drug-shows-rapid-and-sustained-effect-in-chronic-rhinosinusitis" rel="noreferrer noopener">Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis</a>
The ENLIGHTEN 2 trial also met the key secondary endpoints of 3CS at 24 weeks in the full population (i.e., patients with and without nasal polyps) and in the clinically validated SNOT-22 score at 24 weeks, with symptom improvement <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717754/lyra-therapeutics-reports-positive-results-from-the-enlighten-2-phase-3-trial-of-lyr-210-achieving" rel="noreferrer noopener">observed as early as week 4</a>.
<ul class="wp-block-list">
<li>Improvements in SNOT-22 were sustained throughout the trial and were clinically meaningful. More than twice the minimal clinically important difference was observed at week 24 compared to baseline in the LYR-210 group (-22.4 points).</li>
</ul>
Consistent with previous studies, LYR-210 was well-tolerated, with a safety profile similar to sham control.
Data evaluating computed tomography (CT) scans demonstrated numerical improvement in ethmoid sinus opacification in patients who received LYR-210, compared to sham control at week 20 (-2.15; p=0.1809). These data provide objective radiological evidence of improvement with LYR-210 treatment.
<ul class="wp-block-list">
<li>LYR-210 patients showed no difference from sham patients in using corticosteroid rescue medication; however, the LYR-210 patients had fewer endoscopic sinus surgeries than sham control.</li>
</ul>
LYR-210 was well tolerated, with no product-related serious adverse events in the ENLIGHTEN 2 trial.
The ENLIGHTEN program consists of two Phase 3 trials, ENLIGHTEN 1 and ENLIGHTEN 2, to evaluate the efficacy and safety of LYR-210 for CRS.
<ul class="wp-block-list">
<li>While the ENLIGHTEN 2 trial met its primary endpoint and key secondary endpoints, the ENLIGHTEN 1 trial did not meet the primary or secondary endpoints, as&nbsp;<a href="https://www.benzinga.com/news/24/05/38642703/why-lyra-therapeutics-stock-is-down-93-today" target="_blank" rel="noreferrer noopener">reported&nbsp;in May 2024</a>.</li>
</ul>
Lyra also conducted a pooled data analysis of 64 CRS patients with small nasal polyps (grade 1) from the ENLIGHTEN 1 and ENLIGHTEN 2 trials. The data demonstrated a consistent positive trend compared to sham control over 24 weeks in multiple endpoints:
<ul class="wp-block-list">
<li>Improvement in 3CS with LYR-210 compared to sham control at week 24, starting as early as week 4.</li>
<li>Improvement in SNOT-22 score with LYR-210 compared to sham control at week 24, starting as early as week 4.</li>
<li>Improvements in percent ethmoid opacification with LYR-210 compared to sham control at week 20.</li>
<li>Improvements in nasal congestion score (NCS) with LYR-210 compared to sham control at week 24 for patients with moderate to severe NCS at baseline, starting as early as week 4.</li>
<li>Improved nasal polyp score with LYR-210 compared to sham control at week 24.</li>
</ul>
In March,&nbsp;the Food and Drug Administration (FDA) accepted for review&nbsp;GSK plc's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) marketing application for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44084214/gsk-twice-yearly-depemokimab-reduces-nasal-polyp-size-improves-symptoms-in-chronic-rhinosinusitis-goes-under-fda-review-for-two-indications" rel="noreferrer noopener">depemokimab in two indications</a>:
<ul class="wp-block-list">
<li>Add-on maintenance treatment of asthma in adult and pediatric patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller</li>
<li>Add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).</li>
</ul>
Price Action: LYRA stock is up 411.6% at $25.22&nbsp;during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/05/45703024/pfizer-reports-survival-gains-in-colorectal-cancer-study-combo-therapy-cuts-death-risk-by-over-50" target="_blank" rel="noreferrer noopener">Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

LYRA

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

TRVI

Trevi Therapeutics shares are trading higher after the company announced positive topline results from its Phase 2b CORAL trial of Haduvio.

BlueLinx Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXC#NYSE">BXC</a>), a leading U.S. wholesale distributor of building products, and Louisiana-Pacific Corporation ((LP Building Solutions, NYSE:<a href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>), a leading manufacturer of engineered wood building products, are pleased to announce the expansion of their distribution partnership to Springfield, Missouri. The expanded collaboration will include LP's renowned Siding Solutions brands and prefinished solutions, namely LP&#xAE; SmartSide&#xAE; Trim &amp; Siding and LP&#xAE; SmartSide&#xAE; ExpertFinish&#xAE; Trim &amp; Siding. This strategic move expands BlueLinx's stocking footprint of LP&#xAE; SmartSide&#xAE; to 19 locations, spanning five of BlueLinx's regions across the United States.
 &nbsp;

BlueLinx Holdings And LP Building Solutions Announce Expansion Of Distribution Partnership To Springfield, Missouri

Barclays analyst Andrew Mok downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Equal-Weight and lowers the price target from $84 to $65.

Downgrades

Barclays Downgrades Centene to Equal-Weight, Lowers Price Target to $65

ATAI

atai Life Sciences shares are trading higher after the company announced it will merge with Beckley Psytech through a share combination agreement.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Most 22-year-olds don't have to worry about their dad being Bill Gates when they bring someone home—but <a href="https://www.benzinga.com/personal-finance/24/12/42648634/bill-gates-says-his-22-year-old-daughter-told-him-to-never-email-her-so-now-he-sends-her-a-text-letting-her-know-hes-emailing">Phoebe Gates does</a>. And according to her, it's a little bit hilarious… unless you're the guy.
In an <a href="https://youtu.be/PFT7VOPWkF0?si=sfpA5TD5C6JNy0uq">appearance on the "Call Her Daddy" podcast</a> last month, Phoebe sat down with host Alex Cooper—alongside climate activist and business partner Sophia Kianni—to talk about launching their own podcast, "The Burnouts."&nbsp;
But the internet had other priorities: her stories about introducing dates to her famously introverted dad at <a href="https://www.benzinga.com/personal-finance/25/03/44207591/bill-gates-is-a-divorced-grandpa-living-alone-in-gigantic-66000-sq-ft-home-but-wont-be-downsizing-i-cant-i-like-the-houses-i-have">his $63 million lakefront high-tech mansion</a> in Medina, Washington.
"Terrifying, for the guy. For me? Hilarious."
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
That's how Phoebe summed it up. "My dad's, like, pretty socially awkward—he's said he has Asperger's," she explained on the podcast. "To me, it's so funny, but for guys, I think they get, like, really wigged out."
Phoebe didn't just tell—it was full storytime. One of the standout memories? A high school dance.
"My mom had signed my dad up to drive me and the boy to the dance together," she said. "First off, my dad insisted on us listening to NPR the entire 30-minute drive. He stopped for fast food, then he calls the guy—he's like, ‘Be responsible tonight, Max Demonhower.' His name was Maxwell Danenhower. Literally wanted to die."
For Phoebe, these awkward encounters have turned into a kind of test. "Depending on how he reacts, that's how you know if he's gonna be a good guy or not," she told Cooper. If someone can survive a socially anxious Bill Gates mispronouncing their name inside a high-security estate—maybe they're worth keeping around.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
Phoebe also joked that she's the life of the party in a family of self-proclaimed nerds. "It used to be a joke our family would be so boring if I wasn't born," she said. "At the dad-daughter dances my mom would have us go to, I would force my dad to go talk to all the other dads and daughters there. I was like, ‘No. If we're here, we're going to socialize. We've got to work this room, Bill.'"
And don't even try to challenge them to a game night. "You do not want to play a board game with the two of us," she warned. "That's actually worse than introducing a guy to my dad."
Bringing home a date is nerve-wracking enough. Bringing them into a tech billionaire's $63 million mansion where they'll be grilled by a man who <a href="https://www.benzinga.com/personal-finance/25/05/45210851/bill-gates-daughter-says-she-literally-never-hears-him-talk-about-microsoft-and-finds-it-so-funny-he-wouldnt-let-her-drop-out-like-he-di">co-founded Microsoft </a>and prefers NPR over small talk? Brutal.
But Phoebe's take? If they can't handle that, they probably weren't "the guy" anyway.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

Bill Gates' 22-Year-Old Daughter Says It's 'Terrifying' For The Boys She Brings Home to Meet Her 'Socially Awkward' Dad in His $63 Million Mansion

KYMR

Kymera Therapeutics shares are trading higher after the company announced clinical data for its Phase 1 Healthy volunteer study of KT-621.

Leerink Partners analyst Andrew Berens downgrades Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) from Outperform to Market Perform and lowers the price target from $10 to $9.

ARVN

Leerink Partners Downgrades Arvinas to Market Perform, Lowers Price Target to $9

Stifel analyst Brian Brophy maintains Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) with a Buy and raises the price target from $130 to $141.

Stifel Maintains Buy on Limbach Holdings, Raises Price Target to $141

VERA

Vera Therapeutics shares are trading higher after the company announced its ORIGIN Phase 3 trial has met its primary endpoint.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/30/final-trades-jpmorgan-meta-abbvie-and-gap.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown, CEO of Ritholtz Wealth Management, said he is staying long on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), adding that the company has the greatest <a href="https://www.benzinga.com/quote/JPM">CEO ever in banking</a>.
Supporting his views, several analysts, including, Baird, Morgan Stanley, RBC Capital, Piper Sandler and TD Securities, raised their price targets on the stock on May 20.
Kevin Simpson, Capital Wealth Planning CIO, said Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has tons of free cash flow.
As per recent news, Meta and Palmer Luckey-led defense tech startup Anduril Industries announced a partnership to develop rugged VR/AR headsets for the U.S. Army on May 29.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners named AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) as his final trade.
On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie's Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy.
Stephanie Link, Hightower chief investment strategist, picked The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) as her final trade.
Supporting her view, Gap reported quarterly earnings of 51 cents per share on May 29, beating the consensus estimate of 45 cents. Quarterly revenue came in at $3.46 billion, beating the Street estimate of $3.42 billion.
Price Action:
<ul class="wp-block-list">
<li>JPMorgan shares fell 0.1% to close at $264.00 on Friday.</li>
<li>Meta gained 0.4% to close at $647.49 on Friday.</li>
<li>AbbVie shares rose 0.3% to settle at $186.11 during the session.</li>
<li>Gap shares dipped 20.2% to close at $22.31 on Friday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Large Cap

Long Ideas

ABBV

Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'

As of June 2, 2025, three stocks in the utilities sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Korea Electric Power Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>)</h3>
<ul class="wp-block-list">
<li>On May 1, Korea Electric Power filed 2024 Annual Report on Form 20-F. The company's stock jumped around 19% over the past month and has a 52-week high of $11.43.</li>
<li>RSI Value: 72.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>KEP Price Action: Shares of Korea Electric Power gained 1.4% to close at $11.05 on Friday.</li>
<li>Edge Stock Ratings: 92.17 Momentum score with Value at 99.83. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/kep"><img loading="lazy" decoding="async" width="492" height="176" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02081844/image-5.png" alt="" class="wp-image-935087" style="width:386px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02081844/image-5.png 492w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02081844/image-5-300x107.png 300w" sizes="(max-width: 492px) 100vw, 492px" /></a></figure>
<h3 class="wp-block-heading">NRG Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</h3>
<ul class="wp-block-list">
<li>On May 12, NRG Energy reported better-than-expected first-quarter financial results. "NRG achieved exceptional financial and operational performance in the first quarter. Every part of our organization operated at a high level to meet customer and market needs amidst the backdrop of increasing power demand," said Larry Coben, Chair, President, and Chief Executive Officer. The company's stock gained around 34% over the past month and <a href="https://www.benzinga.com/quote/NRG">has a 52-week high</a> of $161.78.</li>
<li>RSI Value: 72.9</li>
<li>NRG Price Action: Shares of NRG rose 0.9% to close at $155.90 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Constellation Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Constellation Energy reported mixed first-quarter 2025 results. Revenue in the first quarter was $6.79 billion, an increase of 10.2% year over year, beating the consensus of $5.44 billion. Constellation CFO Dan Eggers said, "Our generation fleet performed well to start the year with our nuclear plants achieving a 94.1% capacity factor and our natural gas operations attaining a dispatch match rate of 99.2%. Our consistent operational and financial performance continues to drive value for our owners." The company's stock gained around 24% over the past month and has a <a href="https://www.benzinga.com/quote/CEG">52-week high</a> of $352.00.</li>
<li>RSI Value: 71.1</li>
<li>CEG Price Action: Shares of Constellation Energy gained 0.9% to close at $306.15 on Friday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

Top 3 Utilities Stocks That May Crash In June

Entrepreneur and real estate mogul Grant Cardone is sounding off on the financial habits keeping Americans stuck in the middle class. In a recent <a href="https://www.youtube.com/watch?v=RamGV7rZqIY">appearance</a> on &#8220;My View with Lara Trump&#8221; on Fox News, Cardone laid out a roadmap to financial freedom that goes against conventional wisdom—and popular personal finance gurus like Dave Ramsey.
<h2 class="wp-block-heading">Middle Class: A Myth?</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Warning to the middle class, "Get out!" Quit saving money Quit buying homes Quit saving for retirement Quit borrowing for college On The View with <a href="https://twitter.com/LaraLeaTrump?ref_src=twsrc%5Etfw">@LaraLeaTrump</a> <a href="https://t.co/osiQIj4GCF">pic.twitter.com/osiQIj4GCF</a>
&mdash; Grant Cardone (@GrantCardone) <a href="https://twitter.com/GrantCardone/status/1926649212080467999?ref_src=twsrc%5Etfw">May 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
&#8220;Middle class is mythology,&#8221; Cardone said, adding that inflation, <a href="https://www.benzinga.com/25/05/45561879/highest-mortgage-costs-since-february-push-home-buyers-away-even-as-housing-inventory-hits-five-year-high">high mortgage costs</a> and rising food prices are <a href="https://www.benzinga.com/personal-finance/25/05/45484397/the-middle-class-is-dead-why-so-many-millennials-feel-stuck-despite-making-more-than-previous-generations">crushing working families</a>. &#8220;My encouragement to the middle class is get out of it. Once again, move yourself up so there&#8217;s prosperity and abundance—and not just putting everything on a credit card in life.&#8221;
Cardone, who was raised by a single mother, said he&#8217;s been through it and wants people to rethink the old advice. He argued that the reason most people are financially stuck is because they&#8217;re doing what they were told to do: save money, buy a house, save for retirement and borrow for college. He says those strategies simply don&#8217;t work anymore.
&#8220;The middle class has been left behind because they&#8217;ve been saving money and doing the right things—and it&#8217;s not working,&#8221; Cardone said.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
Instead, he said people should start doing what the wealthy do. That includes using tax advantages, making smart investments, and not leaving money sitting in a savings account. &#8220;Actually put money to work,&#8221; he said. &#8220;That&#8217;s why I&#8217;m excited about President Trump. I&#8217;ve reduced my tax bill as low as I could, and you should too.&#8221;
<h2 class="wp-block-heading">Trump&#8217;s Economy And Entrepreneur Incentives</h2>
Cardone praised President Donald Trump&#8217;s policies for giving business owners room to grow. &#8220;If you&#8217;re an entrepreneur, you need incentives, rewards to take those risks,&#8221; he said. He contrasted that with his experience in California, where he says taxes and regulations punished him every time he tried to expand.
Cardone also pushed back on the idea that financial struggles are purely individual failings. &#8220;If a mass group of people suffer from the same thing, it&#8217;s not their fault anymore,&#8221; he said. &#8220;It&#8217;s because they&#8217;ve all been taught the same thing.&#8221;
He called most Americans financially illiterate &#8220;by design&#8221; and said the solution is to reeducate people with strategies that actually build wealth.
See Also: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
<h2 class="wp-block-heading">Advice That Contradicts Ramsey And The Basics</h2>
Cardone's message runs counter to the kind of advice pushed by financial figures like Dave Ramsey, who encourages people to <a href="https://www.benzinga.com/personal-finance/24/12/42746966/debt-and-broke-are-the-norm-says-dave-ramsey-explains-why-normal-isnt-working-for-most-americans-and-how-to-take-control-of-your-money">stay out of debt</a>, buy homes, and save for emergencies. Instead, Cardone believes those old strategies are part of the problem—and not the way out.
&#8220;We need to re-indoctrinate people to what wealthy people do,&#8221; he said. &#8220;<a href="https://www.benzinga.com/money/how-to-reduce-taxable-income-for-high-earners">Use tax advantages</a> and make good investments.&#8221;
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Image: Shutterstock

Grant Cardone Says If You Want To 'Get Out' Of The Middle Class, You Need To Quit Saving Money, Buying Homes, Or Borrowing For College

Press Releases

PepGen Announces Appointment of Two New Directors to its Board

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

Comments

PepGen

PepGen (PEPG) オプション

PepGen (NASDAQ:PEPG) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル